Defendant
1 case as defendant.
Ellodi Pharmaceuticals, L.P. is a privately held, specialty pharmaceutical company founded in 2020 with headquarters in Blue Bell, Pennsylvania. The company was formed by private equity firm TPG Capital to continue the clinical development of a specific drug asset spun out of Adare Pharmaceuticals. As a clinical-stage company, it is small, with an estimated 11-20 employees.
The company's operations are focused on the clinical development of a single product candidate: APT-1011. This drug is a novel, orally disintegrating tablet formulation of the corticosteroid fluticasone propionate, designed for the topical treatment of Eosinophilic Esophagitis (EoE), a rare, chronic allergic inflammatory disease of the esophagus. Ellodi is advancing APT-1011 through Phase 3 clinical trials. The drug has received Orphan Drug Designation in the U.S. and Europe.
As an operating company focused on bringing its own product to market, Ellodi Pharmaceuticals' patent litigation posture is that of a technology developer defending its intellectual property. The company is listed as the defendant in one case at the Patent Trial and Appeal Board (PTAB), initiated by a competitor.
The notable tracked case is a Post-Grant Review proceeding, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., filed in 2025. In this action, Dr. Falk Pharma, a German pharmaceutical company with a competing product for EoE, is challenging the validity of an Ellodi patent for "orally administered corticosteroid compositions." This proceeding is part of a broader dispute between the two companies over patents related to treatments for eosinophilic esophagitis.
Post-Grant Review (PGR) filed by petitioner Dr. Falk Pharma GmbH, challenging the validity of claims 1-34 of the '598 patent. The grounds for the challenge include lack of written description and anticipation.